Advances in experimental medicine and biology
2024
Berend Olivier, Jocelien D A Olivier
11 citations
Major depressive disorder (MDD) is a highly prevalent psychiatric disorder, associated with substantial burden and large economical costs. Notwithstanding various conventional antidepressant treatment options, a large portion of depressed people (ca. 30%) fails to respond to first-line treatment, resulting in treatment-resistant depression (TRD). Although non-response to multiple antidepressant...
Pakistan Journal of Medical and Health Sciences
December 28, 2023
Jawad Hameed, Roheena Wadud
Introduction: Ketamine, traditionally known for its anesthetic properties, is now being explored for its rapid-acting therapeutic effects in various psychiatric and pain-related disorders. Its emerging role in managing treatment-resistant depression (TRD), chronic pain, and post-traumatic stress disorder (PTSD) is supported by recent clinical evidence. Objective: To evaluate the effectiveness...
Pharmaceutics
December 22, 2023
Ludivine Boudieu, Myriam Mennetrier, Pierre-Michel Llorca et al.
22 citations
Ketamine and its enantiomers represent an innovative glutamatergic agent as a treatment for individuals with treatment-resistant depression (TRD) and major depressive disorder (MDD) with suicidal ideation and behavior. Intranasal (IN) formulations could allow for quick onset of action on depressive symptoms as well as a reduction in side effects by bypassing the blood–brain barrier compared...
Brain Sciences
December 22, 2023
Nicolas A. Nunez, Boney Joseph, Rakesh Kumar et al.
20 citations
Ketamine has shown rapid antidepressant and anti-suicidal effects in treatment-resistant depression (TRD) with single and serial intravenous (IV) infusions, but the effectiveness for depressive episodes of bipolar disorder is less clear. We conducted an updated systematic review and meta-analysis to appraise the current evidence on the efficacy and tolerability of ketamine/esketamine in bipolar...
Iranian Journal of Psychiatry and Behavioral Sciences
December 20, 2023
Gholamreza KheirAbadi, Shirin Golkar
Background: Treatment-resistant Depression (TRD) does not respond to conventional treatments. Despite the efforts made to control depression, the outcomes are controversial and inconclusive. New strategies such as ketamine use are accompanied by promising outcomes; however, the best dosage remains a question. Objectives: The current study aimed to compare the effect of 1 and 2 mg/kg of oral...
Frontiers in Psychiatry
December 8, 2023
Alina Wilkowska, Wiesław Jerzy Cubała
10 citations
Bipolar depression constitutes a major problem in psychiatry. It correlates with high suicidality, treatment resistance, chronicity, and poor quality of life. Registered treatment for bipolar depression is limited and insufficient. There is an urgent need for implementing new therapeutic strategies. Intranasal ketamine’s enantiomer—esketamine is a novel rapid-acting antidepressant with proven...
JAMA Psychiatry
December 1, 2023
Chittaranjan Andrade
This Viewpoint discusses ketamine and its new and experimentally investigated on- and off-label indications that span different medical disciplines.
JAMA Psychiatry
December 1, 2023
Sanjay J. Mathew, Manish K. Jha, Amit Anand
8 citations
This Viewpoint examines key issues stemming from several recent reports of electroconvulsive therapy (ECT) vs ketamine for improving depressive symptoms in treatment-resistant depression (TRD).
medRxiv Preprint Server
December 1, 2023
Brandon Taraku, Joana R Loureiro, Ashish K Sahib et al.
1 citation
preprint
Dysfunctional reward processing in major depressive disorder (MDD) involves functional circuitry of the habenula (Hb) and nucleus accumbens (NAc). Ketamine elicits rapid antidepressant and alleviates anhedonia in MDD. To clarify how ketamine perturbs reward circuitry in MDD, we examined how serial ketamine infusions (SKI) modulate static and dynamic functional connectivity (FC) in Hb and NAc...
Pharmacological Reports
December 1, 2023
Magdalena Kolasa, Agata Faron-Górecka
18 citations
Treatment-resistant depression (TRD) is a subgroup of major depressive disorder in which the use of classical antidepressant treatments fails to achieve satisfactory treatment results. Although there are various definitions and grading models for TRD, common criteria for assessing TRD have still not been established. However, a common feature of any TRD model is the lack of response to at least...